Opus Genetics to Participate in Chardan’s 9th Annual
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or…
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
Opus Genetics, Inc. Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular…
Opus Genetics Reports Inducement Grant Under Nasdaq Listing
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical…
Opus Genetics Inherited Retinal Disease Programs Featured
RESEARCH TRIANGLE PARK, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq:IRD), a clinical-stage biopharmaceutical company…
Opus Genetics’ BEST1 Gene Therapy IND Cleared by FDA
Opus Genetics (Nasdaq: IRD) has received FDA clearance for its…
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
Opus Genetics, Inc. – Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data…
Opus Genetics and the Global RDH12 Alliance Partner to
Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis (RDH12-LCA) RESEARCH TRIANGLE…